Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2006

View Archived Issues

Pfizer presents novel renin inhibitors at 231st ACS National Meeting

Johnson & Johnson profile their new 11beta-HSD1 inhibitor

DIN-106935: a mixed ion channel inhibitor

AMG-131: novel modulator of PPARgamma for type 2 diabetes

Two activators of ferric sGC from sanofi-aventis

Antiproliferative efficacy of BMS-554417, an IGF-IR inhibitor

Korean approval for Quinvaxem pentavalent vaccine

Eisai seeks Japanese approval for Pariet in nonerosive GERD

Draximage realigns R&D priorities

Immtech begins pivotal study of pafuramidine maleate

Idera secures funding to advance pipeline

Elixir acquires rights to Glufast

Geron signs agreements with U. of Oxford for dendritic cell production

FemmePharma opens IND for topical cream to treat breast pain

Chinese data support efficacy of telbivudine in chronic hepatitis B

Akzo Nobel updates pipeline status

SD's nano-emulsion paclitaxel formulation demonstrates efficacy in preclinical tests

Japanese cooperative marketing of Abbott and Dainippon Sumitomo comes to end

Lundbeck begins phase I trials for Lu-AA34893 for depression

Rituximab well tolerated, beneficial in steroid-refractory graft-versus-host disease

Recent patents disclose novel antiinfective agents

New treatments for hepatitis C described in recent patent literature

Additional treatment and switching therapy effective in treating resistant depression

New analgesic agents imparted in recent patents

New study data on 7-valent vaccination for invasive pneumococcal disease presented

Exelixis advances XL-784 into phase II for diabetic nephropathy

Levemir made available in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...